Dose selection for prostate cancer patients based on dose comparison and dose response studies

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 4, 2000, Pages 823-832

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Pinover, Wayne H ^a   Horwitz, Eric M ^a   Price, Robert A ^a   Schultheiss, Timothy ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

3D conformal radiation; Dose escalation; Prostate cancer

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE;

DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 0034002392     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00498-8     Document Type: Article

References (29)

1. Hanks G.E., Schultheiss T.E., Hanlon A.L., Hunt M., Lee W.R., Epstein B.E., Coia L.R. Dose escalation in the conformal treatment of prostate cancer Optimization is made possible by understanding the dose responses for control of cancer and late morbidity . Int J Radiat Oncol Biol Phys. 36:1996;197.
2. Hanks G.E., Schultheiss T.E., Hanlon A.L., Hunt M., Lee W.R., Epstein B.E., Coia L.R. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int J Radiat Oncol Biol Phys. 37:1997;543-550.
3. Hanks G.E., Hanlon A.L., Schultheiss T.E., Pinover W.H., Movsas B., Epstein B.E., Hunt M.S. Dose escalation with 3D conformal treatment Five year outcomes, treatment optimization and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
4. Hanks G.E. Strategies for improving the outcome of patients with poor prognosis prostate cancer. Acta Oncol. 37:1998;5-10.
5. Leibel S.A., Heimann R., Kutcher G.J., Zelefsky M.J., Burman C.B., Melain E., Orazem J.P., Mohan R., LoSasso T.J., Lo Y.C., Wiseberg J., Chapman D.S., Ling C.C., Fuks Z. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate Preliminary results of a phase I dose-escalation study . Int J Radiat Oncol Biol Phys. 28:1993;55-65.
6. Zelefsky M.J., Leibel S.A., Kutcher G.J., Kelson S., Ling C., Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am. 1:1995;142-150.
7. Zelefsky M., Leibel S., Gaudin P., Kutcher G., Fleshner N., Venkatramen E., Reuter V., Fair W., Ling C., Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
8. Pollack A., Zagars G. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Physics. 39:1997;1011-1018.
9. Fukanaga-Johnson N., Sandler H.M., McLaughlin W., Strawderman M.S., Grijalva K.H., Kish K.E., Lichter A.L. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;311-318.
10. Hanks G. Progress in 3D conformal radiation treatment of prostate cancer. Acta Oncol. In press.
11. Hanks G., Hanlon A., Pinover W., Horwitz E., Schultheiss T. Survival advantage for prostate cancer patients treated with high dose 3D conformal radiation. Cancer J Sci Am. 5:1999;152-158.
12. Cox J., Grignon D., Kaplan R., Parsons J., Schellhammer P. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
13. ICRU Report No. 50. International Commission on Radiation Units and Measurements: Prescribing, recording, and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993.
14. Hanks G, Schultheiss T, Price R, McNeeley S, Pinover W, Horwitz E, Hanlon A. Fox Chase Cancer Center: The transition from 3D CRT to IMRT after ten years of clinical experience. International Symposium presented by Baylor College of Medicine, Houston, TX; 1999.
15. Anderson P., Hanlon A., Patchefsky A., Al-Saleem T., Hanks G. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys. 41:1998;1087-1092.
16. Bonin S., Hanlon A., Lee W., Movsas B., Al-Saleem T., Hanks G. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer. 79:1997;75-80.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457.
18. SAS/STAT users guide, version 6. 1989;846 SAS Institute, Cary, NC.
19. Partin A., Kattan M., Subong E., Walsh P., Wojno K., Oesterling J., Scardino P., Pearson J. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer A multi-institutional update . JAMA. 277:1997;1445-1451.
20. Kalbfleisch J.D., Ross L.P. The statistical analysis of failure time data. 1980;John Wiley & Sons, New York.
21. Talcott J, Clark J, Stark P, Nadir B, Ragde H. Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of treated patients. American Society of Clinical Oncology - Program Proceedings 1999; 18:311a.
22. Fowler F., Barry M., Lu-Yao G., Wasson J., Roman A., Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life Results from a Medicare survey . Urol. 45:1995;1007-1013.
23. Talcott J., Rieker P., Clark J., Propert K., Weeks J., Beard C., Wishnow K., Kaplan I., Loughlin K., Richie J., Kantoff P. Patient-reported symptoms after primary therapy for early prostate cancer Results of a prospective cohort study . J Clin Oncol. 16:1998;275-283.
24. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T., Collette L., Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
25. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., Hanks G.E., Coughlin C.T., Porter A. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy Report of RTOG 85-31 . J Clin Oncol. 15:1997;1013-1021.
26. Roach M., Meehan S., Kroll S. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 156:1996;1719-1723.
27. Pollack A., Zagars G.K., Starkschall G., Childress C., Kopplin S., Boyer A.L., Rosen I.I. Conventional vs. conformal radiotherapy for prostate cancer Preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;555-564.
28. Zelefsky M., Wallner L., Ling C., Raben A., Hollister T., Wolfe T., Grann A., Gaudin P., Fuks Z., Leibel S. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 17:1999;517-522.
29. Talcott J., Rieker P., Propert K., Clark J., Wishnow K., Loughlin K., Richie J., Kantoff P. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 89:1997;1117-1123.